In a bid to bolster its immunology portfolio, GSK has agreed to acquire CMG1A46 from Chimagen Biosciences for a total transaction value of approximately US$850 M. Through the deal, which involves a US$300 M upfront payment, GSK will gain access to CMG1A46, an investigational dual CD19 and CD20-targeted T cell engager with the potential to deplete uncontrolled B cells present in autoimmune diseases such as lupus. The acquisition will allow GSK to broaden its immunology portfolio as well as prepare for the upcoming patent expiry of its key asset, Benlysta (belimumab).